BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

...resistant Enterobacterales , Pseudomonas aeruginosa and Acinetobacter baumannii . REPAIR’s portfolio companies also include Curza, Entasis Therapeutics Inc....
...in May and is open to all companies worldwide. Inhua Muijrers-Chen, Associate Editor Novo Holdings A/S Spero Therapeutics Inc. Entasis Therapeutics Inc. Curza Procarta...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

...Pseudomonas aeruginosa and Acinetobacter baumannii . REPAIR’s portfolio companies also include Curza [eds: full name], Entasis Therapeutics Inc....
...in May and is open to all companies worldwide. Inhua Muijrers-Chen, Associate Editor Novo Holdings A/S Spero Therapeutics Inc. Entasis Therapeutics Inc. Curza Procarta...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...Schindler was VP, clinical development and executive medical director at H3 Biomedicine Inc. Antibacterial company Entasis Therapeutics Inc....
...Inc. Genmab A/S Kintai Therapeutics Inc. Aerie Pharmaceuticals Inc. Oasmia Pharmaceutical AB Rafael Pharmaceuticals Inc. Arvelle Therapeutics GmbH Ovid Therapeutics Inc. Checkmate Pharmaceuticals Inc. Entasis Therapeutics Inc. Evaxion...
BioCentury | Aug 23, 2019
Politics & Policy

Coalition forms to push changes in antimicrobial payment system

...Eric Kimble and Ruben Tommasi, chief commercial officer and CSO, respectively, of antibacterial therapy company Entasis Therapeutics Inc....
BioCentury | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

...Sutro Biopharma Inc. (NASDAQ:STRO). Matsui is a former EVP at Biogen Inc. (NASDAQ:BIIB). Antibiotic company Entasis Therapeutics...
...CFO of BioDelivery Sciences International Inc. (NASDAQ:BDSI). Mary Romeo, Staff Writer and Jonathan Block, Associate Editor Biogen Biogen Inc. Entasis Therapeutics Inc. Immunome...
BioCentury | Apr 24, 2019
Company News

Management tracks: Portola, Assembly, Entasis

...Knox as SVP, clinical development. Knox was VP, clinical research at Gilead Sciences Inc. (NASDAQ:GILD). Entasis Therapeutics...
...services for use in drug development and personalized cancer treatment decisions. BioCentury Staff Assembly Biosciences Inc. Caris Life Sciences Entasis Therapeutics Juvenescence...
BioCentury | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

...chemistry did not decrease avibactam’s activity. At least two companies are developing oral β-lactamase inhibitors. Entasis Therapeutics Inc.’s...
...Dublin, Ireland Arixa Pharmaceuticals Inc., Palo Alto, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Entasis Therapeutics Inc....
BioCentury | Feb 11, 2019
Distillery Therapeutics

Infectious disease

...Next steps could include testing the compound in animal models of additional Gram-positive bacterial infections. Entasis Therapeutics Inc....
BioCentury | Jan 25, 2019
Financial News

Novo's REPAIR fund investments total €18M in 2018

...Novo Holdings A/S (Hellerup, Denmark) said its REPAIR Impact Fund invested in antibacterial companies Entasis Therapeutics Holdings...
...Makes First Investment in Swiss Antibiotic Company" ). Novo Holdings A/S, Hellerup, Denmark Business: Infectious Sandi Wong Entasis Therapeutics Inc. MinervaX...
BioCentury | Jan 23, 2019
Company News

Management tracks: GSK, A*STAR, Moderna

...the $165 million antimicrobial resistance fund, which launched in February 2018, made 2018 investments in Entasis Therapeutics...
Items per page:
1 - 10 of 43
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

...resistant Enterobacterales , Pseudomonas aeruginosa and Acinetobacter baumannii . REPAIR’s portfolio companies also include Curza, Entasis Therapeutics Inc....
...in May and is open to all companies worldwide. Inhua Muijrers-Chen, Associate Editor Novo Holdings A/S Spero Therapeutics Inc. Entasis Therapeutics Inc. Curza Procarta...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

...Pseudomonas aeruginosa and Acinetobacter baumannii . REPAIR’s portfolio companies also include Curza [eds: full name], Entasis Therapeutics Inc....
...in May and is open to all companies worldwide. Inhua Muijrers-Chen, Associate Editor Novo Holdings A/S Spero Therapeutics Inc. Entasis Therapeutics Inc. Curza Procarta...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...Schindler was VP, clinical development and executive medical director at H3 Biomedicine Inc. Antibacterial company Entasis Therapeutics Inc....
...Inc. Genmab A/S Kintai Therapeutics Inc. Aerie Pharmaceuticals Inc. Oasmia Pharmaceutical AB Rafael Pharmaceuticals Inc. Arvelle Therapeutics GmbH Ovid Therapeutics Inc. Checkmate Pharmaceuticals Inc. Entasis Therapeutics Inc. Evaxion...
BioCentury | Aug 23, 2019
Politics & Policy

Coalition forms to push changes in antimicrobial payment system

...Eric Kimble and Ruben Tommasi, chief commercial officer and CSO, respectively, of antibacterial therapy company Entasis Therapeutics Inc....
BioCentury | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

...Sutro Biopharma Inc. (NASDAQ:STRO). Matsui is a former EVP at Biogen Inc. (NASDAQ:BIIB). Antibiotic company Entasis Therapeutics...
...CFO of BioDelivery Sciences International Inc. (NASDAQ:BDSI). Mary Romeo, Staff Writer and Jonathan Block, Associate Editor Biogen Biogen Inc. Entasis Therapeutics Inc. Immunome...
BioCentury | Apr 24, 2019
Company News

Management tracks: Portola, Assembly, Entasis

...Knox as SVP, clinical development. Knox was VP, clinical research at Gilead Sciences Inc. (NASDAQ:GILD). Entasis Therapeutics...
...services for use in drug development and personalized cancer treatment decisions. BioCentury Staff Assembly Biosciences Inc. Caris Life Sciences Entasis Therapeutics Juvenescence...
BioCentury | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

...chemistry did not decrease avibactam’s activity. At least two companies are developing oral β-lactamase inhibitors. Entasis Therapeutics Inc.’s...
...Dublin, Ireland Arixa Pharmaceuticals Inc., Palo Alto, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Entasis Therapeutics Inc....
BioCentury | Feb 11, 2019
Distillery Therapeutics

Infectious disease

...Next steps could include testing the compound in animal models of additional Gram-positive bacterial infections. Entasis Therapeutics Inc....
BioCentury | Jan 25, 2019
Financial News

Novo's REPAIR fund investments total €18M in 2018

...Novo Holdings A/S (Hellerup, Denmark) said its REPAIR Impact Fund invested in antibacterial companies Entasis Therapeutics Holdings...
...Makes First Investment in Swiss Antibiotic Company" ). Novo Holdings A/S, Hellerup, Denmark Business: Infectious Sandi Wong Entasis Therapeutics Inc. MinervaX...
BioCentury | Jan 23, 2019
Company News

Management tracks: GSK, A*STAR, Moderna

...the $165 million antimicrobial resistance fund, which launched in February 2018, made 2018 investments in Entasis Therapeutics...
Items per page:
1 - 10 of 43